• Rheumatoid Arthritis
    • Désirée M F M Van Der Heijde
    • Désirée M F M van der Heijde: Influence Statistics

      Désirée M F M van der Heijde

      Désirée M F M van der Heijde

      Show email address

      Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands | Rheumatology, LUMC, Leiden, The Netherlands | Department of Rheumatology, Leiden ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Désirée M F M van:Expert Impact

      Concepts for whichDésirée M F M vanhas direct influence:Rheumatoid arthritis,Ankylosing spondylitis,Radiographic progression,Psoriatic arthritis,Axial spondyloarthritis,Patients ankylosing spondylitis,2 years,Inflammatory arthritis.

      Désirée M F M van:KOL impact

      Concepts related to the work of other authors for whichfor which Désirée M F M van has influence:Rheumatoid arthritis,Ankylosing spondylitis,Radiographic progression,Necrosis factor,Rheumatic diseases,Monoclonal antibodies.

      KOL Resume for Désirée M F M van der Heijde


      Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands


      Division of Rheumatology and Research, Diakonhjemmet Hospital, Oslo, Norway

      Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands.

      Director of Imaging Rheumatology, Leiden University Medical Center, Leiden, NETHERLANDS

      Leiden University Medical Center, Leiden, the Netherlands


      Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.

      Rheumatology, Diakonhjemmet Hospital, Norway


      Department of Rheumatology, Leiden, The Netherlands

      VIB Inflammation Research Center, Ghent University, Ghent, Belgium


      Leiden University Medical Center, Albinusdreef 2, 2333, Leiden, ZA, The Netherlands

      Department of Rheumatology.


      From the Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Immuno-Rheumatology Center, St. Luke's International Hospital, St. Luke's International University, Tokyo, Japan; Eli Lilly and Company, Indianapolis, Indiana, USA; Laboratoires Lilly France, Neuilly, France; Department of Rheumatology, Swedish Medical Center; University of Washington, Seattle, Washington, USA.

      Désirée van der Heijde: Leiden University Medical Centre, Leiden, The Netherlands

      C. Charles-Schoeman, MD, MS, Associate Professor of Medicine, UCLA; D. van der Heijde, MD, PhD, Professor of Rheumatology, Leiden University Medical Center; G.R. Burmester, MD, Professor of Medicine and Director, Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin Free University and Humboldt University of Berlin; P. Nash, MBBS, FRACP, Director, Rheumatology Research Unit, Nambour Hospital, and Associate Professor, Department of Medicine, University of Queensland; C.A. Zerbini, MD, Director, Centro Paulista de Investigação Clinica; C.A. Connell, PhD, Senior Director of Clinical Research, Pfizer Inc., Groton; H. Fan, MS, Statistician/Director, Pfizer Inc., Collegeville; K. Kwok, MS, Director of Biostatistics, Pfizer Inc., New York; E. Bananis, PhD, Medical Director, Pfizer Inc., New York; R. Fleischmann, MD, Co-medical Director, Metroplex Clinical Research Center, and Clinical Professor, Department of Internal Medicine, University of Texas Southwestern Medical Center.

      LUMC, Leiden

      Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Désirée M F M van der Heijde is among the top experts in the world.
      Concept World rank
      sdd threshold #1
      clinically progression sdd #1
      corners vci #1
      axspa patients bmi #1
      haq jsn #1
      repair panel #1
      patients mrisij #1
      qol work productivity #1
      oral triple therapy #1
      b27 carriership #1
      sias cohort #1
      baseline ≤ #1
      positive spinal mri #1
      experts repair #1
      work productivity work #1
      pain thoracic spine #1
      progression imaging #1
      eq5d asdas #1
      50 week #1
      reactive protein level #1
      ibd patients arthropathies #1
      continuous nsaid #1
      controls tpa #1
      sharp heijde method #1
      rs1805010 rs1801275 #1
      10mg tofacitinib #1
      modified sharp #1
      patients radiographic #1
      early axspa definition #1
      clear longitudinal cohort #1
      radiographic progression patients #1
      esr32 #1
      drive—a #1
      5 years basmilin #1
      pfh axspa #1
      czp discontinuation #1
      4vremission #1
      arthrography disease #1
      illness spondylitis life #1
      golimumabtreated patients #1
      nsaids radiographic progression #1
      wrist jsn #1
      sustained low rates #1
      referral models patients #1
      term radiographic #1
      bmi axspa patients #1
      demand nsaid #1
      infliximab spondylitis infliximab #1
      das28esr hda #1
      scoring radiographic #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Désirée M F M van der Heijde

      KOL-Index: 23660

      BACKGROUND: Gout is an inflammatory arthritis that is characterised by the deposition of monosodium urate crystals in synovial fluid and other tissues. The natural history of articular gout is generally characterised by three periods: asymptomatic hyperuricaemia, episodes of acute gout and chronic gouty arthritis. Non-steroidal anti-inflammatory drugs (NSAIDs) including selective cyclo-oxygenase-2 (COX-2) inhibitors (COXIBs) are commonly used to treat acute gout. Published guidelines ...

      Known for Acute Gout | Adverse Events Nsaids | 95 Function | Steroidal Anti | Pain Reduction
      KOL-Index: 22527

      OBJECTIVE: To assess whether it is better to intensively treat all patients with early rheumatoid arthritis (RA) using combinations of drugs or to reserve this approach for patients who do not have an appropriate response (as determined by a Disease Activity Score in 28 joints using the erythrocyte sedimentation rate [DAS28-ESR] of ≥ 3.2 at week 24) to methotrexate (MTX) monotherapy, and to assess whether combination therapy with MTX plus etanercept is superior to the combination of MTX ...

      Known for Mtx Etanercept | Triple Therapy | Sulfasalazine Hydroxychloroquine | Combination Treatment | Rheumatoid Arthritis
      KOL-Index: 22498

      BACKGROUND: At present, biological disease-modifying anti-rheumatic drugs (DMARDs) are the only treatment recommended for patients with ankylosing spondylitis who have not responded to first-line treatment with non-steroidal anti-inflammatory drugs (NSAIDs). The TORTUGA trial investigated the efficacy and safety of filgotinib, an oral selective Janus kinase 1 (JAK1) inhibitor, for the treatment of patients with active ankylosing spondylitis.

      METHODS: In this completed, randomised, ...

      Known for Ankylosing Spondylitis | Janus Kinase | Patients Filgotinib | 2 Trial | Placebo Treatment
      KOL-Index: 22452

      BACKGROUND: Axial spondyloarthritis (axSpA) comprises ankylosing spondylitis (radiographic axSpA) and non-radiographic (nr-)axSpA and is associated with psoriasis, uveitis and inflammatory bowel disease. Non-steroidal anti-inflammatory drugs (NSAIDs) are recommended as first-line drug treatment.

      OBJECTIVES: To determine the benefits and harms of NSAIDs in axSpA.

      SEARCH METHODS: We searched CENTRAL, MEDLINE and EMBASE to 18 June 2014.

      SELECTION CRITERIA: Randomised controlled trials ...

      Known for Ankylosing Spondylitis | Axial Spondyloarthritis | Steroidal Anti | Harms Placebo | Radiographic Progression
      KOL-Index: 20796

      BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs).

      METHODS: In this 12-month, double-blind, active-controlled and placebo-controlled, phase 3 trial, we randomly assigned patients in a 2:2:2:1:1 ratio to receive one of the ...

      Known for Tofacitinib Placebo | Psoriatic Arthritis | Month Patients | Inadequate Response | 10mg Dose
      KOL-Index: 19835

      BACKGROUND: Etanercept and methotrexate are effective in the treatment of rheumatoid arthritis but no data exist on concurrent initiation or use of the combination compared with either drug alone. We aimed to assess combination treatment with etanercept and methotrexate versus the monotherapies in patients with rheumatoid arthritis.

      METHODS: In a double-blind, randomised, clinical efficacy, safety, and radiographic study, 686 patients with active rheumatoid arthritis were randomly ...

      Known for Rheumatoid Arthritis | Etanercept Methotrexate | Combination Treatment | 24 Weeks | Total Sharp Score
      KOL-Index: 19799

      BACKGROUND: Despite optimal therapy with disease-modifying antirheumatic drugs, many people with inflammatory arthritis (IA) continue to have persistent pain that may require additional therapy.

      OBJECTIVES: To assess the benefits and safety of combination pain therapy for people with IA (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and other spondyloarthritis (SpA)). We planned to assess differences in effects between patients on background ...

      Known for Combination Therapy | Inflammatory Arthritis | Ankylosing Spondylitis | Pain Management | Risk Bias
      KOL-Index: 19779

      BACKGROUND: Baricitinib is an oral, reversible inhibitor of the Janus kinases JAK1 and JAK2 that may have therapeutic value in patients with rheumatoid arthritis.

      METHODS: We conducted a 52-week, phase 3, double-blind, placebo- and active-controlled trial in which 1307 patients with active rheumatoid arthritis who were receiving background therapy with methotrexate were randomly assigned to one of three regimens in a 3:3:2 ratio: placebo (switched to baricitinib after 24 weeks), 4 mg of ...

      Known for Rheumatoid Arthritis | Baricitinib Placebo | Week Patients | Joint Damage | Radiographic Progression
      KOL-Index: 19465

      BACKGROUND: The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 subunit, significantly and safely improved psoriatic arthritis in a phase 2 study. DISCOVER-2 was a phase 3 trial to assess guselkumab in biologic-naive patients with psoriatic arthritis.

      METHODS: This phase 3, double-blind, placebo-controlled study was done at 118 sites in 13 countries across Asia, Europe, ...

      Known for Active Psoriatic Arthritis | Patients Guselkumab | 3 Trial | 4 Weeks | Treatment Week
      KOL-Index: 18321

      BACKGROUND: Interleukin 17A is a proinflammatory cytokine that is implicated in the pathogenesis of psoriatic arthritis. We assessed the efficacy and safety of subcutaneous secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis.

      METHODS: In this phase 3, double-blind, placebo-controlled study undertaken at 76 centres in Asia, Australia, Canada, Europe, and the USA, adults (aged ≥18 years old) with active psoriatic arthritis were randomly ...

      Known for Psoriatic Arthritis | Patients Week | Secukinumab 300 | 3 Trial | 75 Placebo
      KOL-Index: 17944

      Objective. To investigate differences between HLA-B27– and HLA-B27+ patients with ankylosing spondylitis (AS).Methods. A total of 1080 patients with AS responded to a questionnaire containing 30 questions; 945 (87.5%) knew their HLA-B27 status, 10% of them being B27–.Results. The average age at disease onset was 27.7 years in B27– and 24.8 years in B27+ AS (P<0.01). The average age at diagnosis was 39.1 and 33.2 years and the average diagnosis delay 11.4 and 8.5 years, respectively. The ...

      Known for Disease Onset | Ankylosing Spondylitis | Average Age | Diagnosis Delay | B27 Patients
      KOL-Index: 17615

      OBJECTIVE: To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX.

      METHODS: Patients who had not previously been treated with MTX with active RA were randomly assigned to receive escalating doses of MTX up to 20 mg/week plus placebo or infliximab at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46. Radiographic joint damage was ...

      Known for Joint Damage | Mtx Infliximab | Early Rheumatoid Arthritis | Radiographic Progression Patients | Baseline Week
      KOL-Index: 17302

      OBJECTIVE: To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti-tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with an inadequate response to MTX therapy alone.

      METHODS: In this 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, 982 patients were randomized 2:2:1 to receive treatment with subcutaneous ...

      Known for Certolizumab Pegol | Active Rheumatoid Arthritis | Placebo Mtx | Physical Function | Phase Iii
      KOL-Index: 17011

      OBJECTIVES: To investigate whether the single-item fatigue question of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Multidimensional Fatigue Inventory (MFI) are appropriate instruments to measure fatigue in ankylosing spondylitis (AS); to identify factors that influence fatigue in AS; and to assess how fatigue in all its aspects is associated with quality of life in AS.

      METHODS: A total of 812 patients with AS were included. Patients completed questionnaires on ...

      Known for Ankylosing Spondylitis | Fatigue Patients | Quality Life | Disease Activity Basdai | Mental Health Status

      Key People For Rheumatoid Arthritis

      Top KOLs in the world
      Paul Emery
      rheumatoid arthritis ankylosing spondylitis radiographic progression
      Josef Sebastian Smolen
      rheumatoid arthritis systemic lupus erythematosus radiographic progression
      James F Fries
      rheumatoid arthritis physical function systemic lupus erythematosus
      John Turner Sharp
      rheumatoid arthritis radiographic progression joint space width
      Frederick J Wolfe
      rheumatoid arthritis work disability rheumatic diseases
      Matthew H Liang
      rheumatoid arthritis systemic lupus erythematosus lyme disease

      Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands | Rheumatology, LUMC, Leiden, The Netherlands | Department of Rheumatology, Leiden University Medical Centre, Leiden, The Netherlands | Rheumatology Department, Lei

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.